Abstract
The bane of virotherapy is the presence of pre-existing antiviral antibodies or the induction of such antibodies after first dose therapy, which potentially could diminish therapeutic efficacy. We are interested to use oncolytic measles virus as a virotherapy agent for multiple myeloma, a disseminated plasma cell malignancy found predominantly in the bone marrow. Though about 50% of myeloma patients do not have protective levels of anti-measles antibodies due to their disease, we are keen to explore strategies to improve virus delivery to the tumor sites for patients that are positive for measles antibodies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
